Eledon Pharmaceuticals Inc
ELDN
NASDAQ
Biotechnology
$3.54
USD
-0.16 (-4.32%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $285.59M
Volume 1.3M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-78.15M
TTM
-310.3%
YoY
Operating Cash Flow
$-68.89M
TTM
-26.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.4 | 4.5 | 4.1 | 4.0 | 4.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 18.0 | 24.7 | 19.1 | 21.5 | 21.2 |
Operating Income | -18.0 | -24.7 | -19.1 | -21.5 | -21.2 |
EBITDA | -18.0 | -24.7 | -19.1 | -21.5 | -21.2 |
Other Income / Expense | 11.5 | 13.5 | 1.6 | 11.1 | -17.8 |
Total Other Income / Expense | 11.5 | 13.5 | 1.6 | 11.1 | -17.8 |
Income Before Income Taxes | -6.5 | -11.2 | -17.5 | -10.4 | -39.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -6.5 | -11.2 | -17.5 | -10.4 | -39.0 |
Consolidated Net Income / Loss | -6.5 | -11.2 | -17.5 | -10.4 | -39.0 |
Net Income Attributable to Common Shareholders | -6.0 | -10.4 | -16.1 | -13.1 | -36.9 |
Basic EPS | -$0.08 | -$0.13 | -$0.21 | -$0.14 | -$0.33 |
Diluted EPS | -$0.08 | -$0.13 | -$0.21 | -$0.14 | -$0.33 |
Basic Shares Outstanding | 77.1M | 77.2M | 77.2M | 95.9M | 112.4M |
Diluted Shares Outstanding | 77.1M | 77.2M | 77.2M | 95.9M | 112.4M |